Neuroprotective Effects of Agomelatine and Vinpocetine Against Chronic Cerebral Hypoperfusion Induced Vascular Dementia

Author(s): Surbhi Gupta, Prabhat Singh, Brij Mohan Sharma, Bhupesh Sharma

Journal Name: Current Neurovascular Research

Volume 12 , Issue 3 , 2015

Become EABM
Become Reviewer
Call for Editor


Chronic cerebral hypoperfusion (CCH) has been considered as a critical cause for the development of cognitive decline and dementia of vascular origin. Melatonin receptors have been reported to be beneficial in improving memory deterioration. Phosphodiesterase-1 (PDE1) enzyme offers protection against cognitive impairments and cerebrovascular disorders. Aim of this study is to explore the role of agomelatine (a dual MT1 and MT2 melatonin receptor agonist) and vinpocetine (selective PDE1 inhibitor) in CCH induced vascular dementia (VaD). Two vessel occlusion (2VO) or bilateral common carotid arteries ligation method was performed to initiate a phase of chronic hypoperfusion in mice. 2VO animals have shown significant cognitive deficits (Morris water maze), cholinergic dysfunction (increased acetyl cholinesterase -AChE) activity alongwith increased brain oxidative stress (decreased brain catalase, glutathione, as well as superoxide dismutase with an increase in malondialdehyde levels), and significant increase in brain infarct size (2,3,5- triphenylterazolium chloride-TTC staining). Treatment of agomelatine and vinpocetine reduced CCH induced learning and memory deficits and limited cholinergic dysfunction, oxidative stress, and tissue damage, suggesting that agomelatine and vinpocetine may provide benefits in CCH induced VaD.

Keywords: 2, 3, 5-triphenylterazolium chloride staining, acetylcholinesterase, brain damage, melatonin receptor, oxidative stress, phosphodiesterase-1 enzyme, two vessel occlusion

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2015
Published on: 06 July, 2015
Page: [240 - 252]
Pages: 13
DOI: 10.2174/1567202612666150603130235
Price: $65

Article Metrics

PDF: 39